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Summary
We investigated the long-term outcome, the incidence of second neoplasms
(SN) and the rate of late adverse effects (LAE) in children with central ner-
vous system (CNS) negative medium/high-risk de novo acute lymphoblastic
leukaemia (ALL), in first complete remission (CR1) at end of late intensifi-
cation, randomized to receive no cranial radiotherapy (No CRT, n = 92)
versus CRT (standard arm, n = 84) in the non-inferiority EORTC 58832
study (1983–1989). Median follow-up was 20 years (range 4–32 years). The
25-year disease-free survival rate (SE) was 674  49% without CRT and
702  50% with CRT. The 25-year incidence of isolated (65  26% vs.
48  23%) and any CNS relapse {87  29% vs. 119  35%; hazard
ratio (HR) 071 [95% confidence interval (CI) 028–179]; test of non-infe-
riority: P = 001} was not increased without CRT. The 25-year SN inci-
dence in CR1 was 79  46% vs. 110  42%. The 25-year event-free and
overall survival rates were quite similar in both arms [595  63% vs.
605  59%, HR 094 (95% CI 057–152), and 781  43% vs.
785  45%, HR 100 (95% CI 053–188)]. Omission of CRT was associ-
ated with dramatic decrease in CNS and endocrine LAE rates. In conclu-
sion, our data suggest that, with proper systemic and intrathecal CNS
prophylaxis, CRT could totally be omitted in CR1 without jeopardizing
survival, while decreasing LAE in childhood ALL.
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Historically, pre-emptive craniospinal or cranial radiotherapy
(CRT) was a standard component of childhood acute lym-
phoblastic leukaemia (ALL) treatment protocols to prevent
central nervous system (CNS) relapses. The emergence of
CRT-related neurotoxicity, endocrine sequelae and second
neoplasms (SN) prompted several authors to investigate
alternative methods of CNS prophylaxis (Green et al., 1980).
Systemic and intrathecal chemotherapy could successfully
replace CRT in protocols for standard-risk ALL. However, in
patients presumed to be at increased risk of CNS relapse, the
omission of CRT remained debatable.
Between 1983 and 1989, we conducted the EORTC studies
58831/2 in order to investigate whether CRT could be omit-
ted in a BFM (Berlin–Frankfurt–M€unster)-oriented protocol
in which systemic and intrathecal chemotherapy was admin-
istered to prevent CNS relapses in patients aged 1–17 years
with CNS-negative de novo ALL, either standard-risk (study
58831), or medium/high-risk (study 58832) (Fig 1). In 2000,
we reported the initial overall results of the efficacy analyses
for both studies 58831 and 58832, at a median follow-up of
94 years (Vilmer et al., 2000). At 10 years, the disease-free
survival (DFS) rate was 676% and the incidence of any and
isolated CNS relapse was 12% and 7% respectively. In the
medium/high-risk group, the patients randomized to receive
intermediate-dose methotrexate (MTX) alone (No CRT arm)
had similar outcomes to those randomized to receive inter-
mediate-dose MTX followed by CRT.
Here, we provide the long-term outcomes of the random-
ization comparing No CRT versus CRT in medium/high-risk
patients included in study 58832, at a median follow-up of
20 years (range 4–32 years). In addition, we evaluated the
incidence of SN and the rate of late adverse effects (LAE) by
treatment arm. Standard-risk patients included in study
58831 are not part of the present analysis, except for the
evaluation of the LAE after different MTX dosages.
Methods
Patient population and treatment protocol
Patients below 18 years with CNS-negative de novo ALL were
eligible in European Organization for Research and Treat-
ment of Cancer (EORTC) studies 58831/2. Treatment stratifi-
cation was based on the risk factor (RF) calculation
according to Langerman et al. (1982). Standard-risk patients
(RF < 12) received No CRT and were treated with four
MTX infusions at 05 g/m2 and six intrathecal MTX injec-
tions. Medium- (RF 12–<17) and high-risk (RF ≥ 17)
patients in complete remission (CR) at the end of consolida-
tion and still in CR at the end of late intensification were
randomized to receive CRT (CRT arm, standard arm) or not
(No CRT arm, experimental arm) before the start of mainte-
nance therapy. Dose of CRT was age-dependent: 16 Gy
under one year of age, 20 Gy under two years and 24 Gy at
C. Piette et al.
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two years or older. Prophylactic CNS therapy consisted of
four intermediate-dose MTX infusions (25 g/m2) during
interval therapy and seven intrathecal MTX injections.
Details on stratification and treatment protocol are provided
in Fig 1.
Data collection
Data were updated by the institutions, based on information
reported by the Belgian Cancer Registry and the French Regis-
tre National des Hemopathies malignes de l’Enfant (for vital
status and SN) or based on their own medical records (for
vital status, disease status, SN and LAE). New medical exami-
nation was encouraged but not mandatory.
Definitions
CNS involvement was defined as the presence of at least one
blast on cytospin with any white blood cells (WBC) in the
cerebrospinal fluid. CNS relapses were categorized as ‘iso-
lated’ or ‘combined’ depending on the occurrence of simulta-
neous relapse at another site. ‘Any CNS’ relapses included
both isolated CNS and combined CNS relapses. ‘Bone
marrow (BM) combined’ relapses were defined as BM
relapses occurring simultaneously with another site of
relapse, except CNS. SN was defined as any malignancy that
occurred after the randomization between CRT and No CRT
and distinct from the initial ALL diagnosis, whatever the
remission status of the patient. Benign tumours were not
considered as SN, except for CNS tumours. Adverse effects
were defined with the Common Terminology Criteria for
Adverse Events (CTCAE), Version 4.0. LAEs were defined as
adverse effects occurring two months or later after ending
first-line therapy or during the first-line therapy (after the
end of re-induction/late intensification) and persisting
two months or more after ending first-line therapy.
Ethics
At the time of the enrolment in studies 58831 and 58832,
informed consent was sought according to local practice of
each participating centre and in accordance with the Declara-
tion of Helsinki. The late side effect project (EORTC study
58LAE, ClinicalTrials.gov Identifier NCT01298388) was
approved by the Ethical Committee of the University Hospi-
tals and informed consent was obtained from all patients
Notes:
1 Per oral (when not specified, administration is intravenous)
² Intrathecal  at the dose of 6 mg < 1 year, 8 mg 1-< 2 year, 10 mg 2-<3 year, 12 mg ≥ 3 year
3 Patients in complete remission at the end of consolidation and still in complete remission after the end of late intensification 
4 Dose according to age : 16 Gy (if age < 1 year), 20 Gy (if age 1-< 2 years) or 24 Gy (if age ≥ 2 years)
Abbreviations:  Ara-C: cytarabine, ASNase: asparaginase, CPM: cyclophosphamide, CR: complete remission, D: day, DEX: dexamethasone, DNR: daunorubicin,  DOXO: doxorubicin, HD: high-dose, IT: 
intrathecal, 6-MP: 6-mercaptopurine, MTX: methotrexate, PRED: prednisone, R: randomization, 6-TG: 6-thioguanine, VCR: vincristine, WBC: white blood cells
MAINTENANCE THERAPY
6-MP 50 mg/m² po daily*
MTX 20 mg/m² po weekly*
* Adjusted to maintain WBC
between 2000 and 3000/mm³
RE-INDUCTION/LATE INTENSIFICATION
DEX 10 mg/m² po D 1-28
tapered over 12 D
VCR 1·5 mg/m² D 1,8,15,22
DOXO 30 mg/m² D 1,8,15,22
ASNase 10000 U/m² D 1,4,8,11
CPM 1 g/m² D 29
6-TG 60 mg/m² po D 29-42
Ara-C 75 mg/m² D 31-34,38-41
CONSOLIDATION
6-MP 60 mg/m² po D 1-28
Ara-C 75 mg/m² 
D 3-6,10-13,17-20,24-27
CPM 1 g/m² D 1,28
MTX IT2 D 3,17
INTERVAL THERAPY
6-MP 25 mg/m² po D 1-56
HD MTX 2·5 g/m² D 8,22,36,50*
MTX IT2 D 8,22,36,50
* Leucovorin 30 mg/m²
6 hours after end of MTX 
infusion, then 15 mg/m² every
6 hours until 48 hours from








PRED 60 mg/m² po1 D 1-28
tapered over 12 D
VCR 1·5 mg/m² D 1,8,15,22
DNR 30 mg/m² D 1,8,15,22
ASNase 5000 U/m² D 1-21
MTX IT2 D 1
EORTC study 58831: standard-risk patients (RF<1·2) in CR at the end of induction
EORTC study 58832: medium- risk patients (RF 1·2-1·69), high- risk patients (RF≥1·7), and standard- risk patients (RF<1·2) not in CR at the end of induction 
MAINTENANCE THERAPY
6-MP 50 mg/m² po daily*
MTX 20 mg/m² po weekly*
* Adjusted to maintain WBC
between 2000 and 3000/mm³
RE-INDUCTION/LATE INTENSIFICATION
DEX 10 mg/m² po D 1-14
tapered over 11 D
VCR 1·5 mg/m² D 1,8
DOXO 30 mg/m² D 1,8
ASNase 10000 U/m² D 1,4,8,11
6-TG 60 mg/m² po D 15-28
Ara-C 75 mg/m² D 17-20, 24-47
CONSOLIDATION
6-MP 60 mg/m² po D 1-28
Ara-C 75 mg/m² 
D 3-6,10-13,17-20,24-27
MTX IT2 D 3
CPM 1 g/m² according to R
INTERVAL THERAPY
6-MP 25 mg/m² po D 1-56
MTX 0·5 g/m² D 8,22,36,50*
MTX IT2 D 8,22,36,50
* Leucovorin 12 mg/m²
24 hours and po 30 hours
after end of MTX infusion.




PRED 60 mg/m² po1 D 1-28
tapered over 12 D
VCR 1·5 mg/m² D 1,8,15,22
DNR 30 mg/m² D 1,8,15,22
ASNase 5000 U/m² D 1-21
MTX IT2 D 1
Fig 1. General scheme of EORTC studies 58831 and 58832.
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alive at the time of the latest follow-up, in accordance with
the national applicable legislation.
Statistical analysis
Endpoints were disease-free survival [DFS; event: relapse,
death in first complete remission (CR1)], incidence of any
CNS and of isolated CNS relapses, incidence of SN at any
stage and in CR1, event-free survival (EFS; event: relapse
without SN, SN in CR1, death in CR1 and without SN),
overall survival (OS) from randomization and rate of LAE
(defined using the CTCAE 4.0 scale). The expected inci-
dence of any CNS relapse in the CRT arm was 10% at
three years. The trial was designed as a non-inferiority trial,
for example to test whether in the No CRT arm, compared
to the CRT arm, the increase of the three-year incidence
of any CNS relapse was ≥10% (null hypothesis) or <10%
(alternative hypothesis). In case the latter hypothesis was
confirmed, the treatment hazard ratio (HR) would be
<212.
Distributions of composite time-to-event endpoints were
estimated according to the Kaplan–Meier technique and
standard errors (SE) of the 25-year estimate rates were
obtained via the Greenwood formula. The estimated HR and
its 95% or 99% confidence interval (CI) were computed
using the Cox model. The cumulative incidence of CNS
relapse and of isolated CNS relapse, subdistributions of DFS,
the cumulative incidence of SN, subdistribution of survival
without SN, and the cumulative incidence of SN in CR1 and
subdistributions of EFS were computed using competing risk
methods (Kalbfleisch & Prentice, 2002). The estimated HR of
the subdistributions and its 95% CI were computed using
the Fine–Gray model. Only for the CNS incidence a statisti-
cal inference was performed; for all others, descriptive statis-
tics were provided. Being a non-inferiority trial (No CRT
versus CRT), all analyses were based on the per-protocol
treatment population: all eligible patients who started the
treatment allocated by randomization. SAS 9.4 statistical soft-
ware (Cary, NC, USA) was used.
Results
A total of 189 patients were randomized in the intent-to-
treat (ITT) study 58832. Among them, 183 were eligible
(three ineligible patients in each arm) and 176 patients were
included in the present per-protocol treatment (PPT) evalua-
tion (one inevaluable patient in the No CRT arm versus six
in the CRT arm): 92 patients in the No CRT arm and 84
patients in the CRT arm (Fig 2). Clinical characteristics were
well balanced in both treatment arms, both in the ITT (data
not shown) and PPT populations (Table I). For the entire
PPT population, the sex ratio M/F was 15, the median age
at diagnosis was four years, and the median age at last fol-
low-up was 22 years. Immunophenotyping was not available
to distinguish B- and T-ALL.
The 25-year DFS rate (SE) was similar in both arms
(674  49% without CRT vs. 702  50% with CRT, Fig
3A, Table I). No relapse occurred after seven years. The 25-
year incidence (SE) of isolated CNS relapse was
65  26% vs. 48  23% in the No CRT and CRT arms
and the 25-year incidence (SE) of any CNS relapse was
87  29% vs. 119  35% respectively (Fig 3A, Table I).
Comparison of the incidence of any CNS relapse between No
CRT and CRT yielded a HR of 071 (95% CI 028–179),
which was significantly lower than 212 (test for non-inferi-
ority: one-sided P = 001), indicating that the increase of the
any CNS relapse incidence without CRT was lower than
10%.
The 25-year SN incidence (SE) at any time and in CR1
was 73  43% without CRT vs. 130  46% with CRT,
and 79  46% without CRT vs. 110  42% with CRT
respectively (Table I). In the No CRT arm, 4 patients out of
92 (43%) had SN vs. 9 out of 84 (107%) in the CRT arm.
Clinical characteristics, SN latency and types, and therapy
given as part of ALL or SN therapy are shown in Table II.
No children below the age of two at diagnosis developed SN.
Patients with SN were mostly females (F/M ratio: 16). The
latency between randomization and SN diagnosis was shorter
for haematological malignancies (median 28 years, range
05–64 years) than for solid tumours (median 212 years,
range 127–286). Two patients had acute myeloid leukaemia
(AML) at 15 and 40 years after randomization. In both
cases, the fingerprint of a secondary leukaemia (t11q23,
monosomia 7, 5q-) was lacking. The difference in SN inci-
dence between both arms was mainly due to a high incidence
of meningiomas in the CRT arm (four patients had menin-
gioma as first SN, one of them had a second meningioma
and one additional patient had a meningioma after a first
AML). Noteworthy, all of them occurred after very long fol-
low-up (range 192–286 years from randomization). Second
or synchronous SN were exclusively observed in patients
treated with CRT, in first- or second-line treatment. One
patient with malignant histiocytosis died of SN, all others
were alive at last follow-up.
The 25-year EFS rate (SE) was similar in both arms:
595  63% without CRT vs. 605  59% with CRT (Fig
3B, Table I) as well as the 25-year OS rate (SE):
781  43% and 785  45% respectively (Fig 3C, Table I).
Data regarding LAE were available for around 25% of the
patients (Table III). Omission of CRT was associated with
dramatic decrease in the rate of CNS LAE. Leukoen-
cephalopathy was reported in 87% of the patients (n = 2)
randomized in the No CRT arm but who received second-
line treatments comprising CRT or total body irradiation
(TBI) vs. 192% (n = 5) in the CRT arm. Cognitive distur-
bance was reported in 188% of the patients in the No CRT
arm (n = 3, two in CR1 and one after a BM relapse treated
with CRT) vs. 421% in the CRT arm (n = 8). Seizures
occurred in 37% of the patients in the No CRT arm (n = 1,
hereditary epilepsy) vs. 143% in the CRT arm (n = 4). In
C. Piette et al.
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the CRT arm, convulsions were secondary to meningiomas
(n = 2), to bilateral subdural effusions after CNS relapse
(n = 1) or to severe encephalopathy occurring during CRT
(n = 1). Finally, strokes were only reported in the CRT arm
(77% of the patients, n = 2), at 6 and 24 years after end of
treatment.
As late neurotoxicity could also be related to intermediate-
dose MTX, we compared the rate of LAE in patients random-
ized for No CRT and treated with intermediate-dose MTX in
study 58832, with that of standard-risk patients treated with-
out CRT and with lower dosage of MTX (05 g/m2) in study
58831 (Fig 1). Decrease in MTX dosage was associated with
lower rates of leucoencephalopathy (16%) and cognitive dis-
turbance (63%) (Table III). Seizures were reported in 109%
of the standard-risk patients (n = 11). In four patients, the
convulsions occurred during maintenance therapy, without
evident aetiology, except in one patient in whom a hypodense
lesion of the left parietal lobe was identified on a computed
Paents included in EORTC study 58831/2 (N = 788):
- de novo ALL
- CNS negave
- ≥ 1 and < 18 years old
Paents included in EORTC study 58832 (N = 189):
- medium-risk paents (RF 1·2-1·69)
- OR high-risk paents (RF≥1·7) 
- OR standard-risk paents (RF<1·2) not in CR at the end of inducon
AND in CR at end of consolidaon and sll in CR at end of late intensificaon





Ineligible paents (N = 3):
- No CR at end of consolidaon (N = 3)
Ineligible paents (N = 3):
- No CR at end of consolidaon (N = 2)





Per protocol treatment populaon (N = 176)
Inevaluable paents (N = 6):
- Early relapse (N = 1)
- Protocol violaon (N = 3)
- Refusal of allocated CRT (N = 2)
Inevaluable paent (N = 1):





Fig 2. Consort diagram of EORTC study 58832.
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tomography scan. In four patients, seizures occurred in CR1,
1–6 years after the end of first-line treatment, without clear
explanation. Convulsions were reported during the treatment
of CNS relapse in three other patients.
Omission of CRT was associated with a decreased rate of
endocrine LAE (Table III). The rate of growth hormone
(GH) deficiency was 185% in the No CRT arm vs. 531% in
the CRT arm. Hypothyroidism or precocious puberty were
observed in none of the patients of the No CRT arm and in
278% and 294% respectively in the CRT arm. Delayed pub-
erty was diagnosed in 105% of the patients in the No CRT
arm vs. 125% in the CRT arm. Finally, we have investigated
the impact of TBI in first- or second-line treatments on the
different endocrine LAE. The observed rate of GH deficiency
was 100% in the TBI group (n = 5) vs. 315% without TBI
(n = 54), the rate of hypothyroidism was 100% with TBI
(n = 3) vs. 61% without TBI (n = 33) and the rate of
delayed puberty was 100% with TBI (n = 2) vs. 61% with-
out TBI (n = 33). Similar trends were observed in study
58831 (see Table SI).
Discussion
With dramatic improvements in the survival of childhood
ALL patients over the last 50 years, the need for a compre-
hensive appraisal of their long-term outcome, including the
late effects of the treatments, has been increasingly recog-
nized. In this context, the benefit–risk balance for the use of
CRT as part of the CNS prophylaxis remained controversial
for patients presumed to be at increased risk of CNS relapse.
Here, we updated, with very-long-term data, the results of
the randomization comparing No CRT versus CRT in med-
ium/high-risk childhood ALL patients included in study
58832 (1983–1989) and evaluated the incidence of SN and
the rate of LAE by treatment arm.
Table I. Distribution of the clinical and disease characteristics and of
the outcome, according to the treatment arm (No CRT versus CRT)
in EORTC study 58832.
No CRT CRT
92 (100%) 84 (100%)
Sex
Male, n (%) 59 (641) 47 (560)
Female, n (%) 33 (359) 37 (440)
Age at diagnosis (years)
<1, n (%) 3 (33) 4 (48)
1–<2, n (%) 14 (152) 9 (107)
2–5, n (%) 34 (370) 34 (405)
6–9, n (%) 26 (283) 24 (286)
≥10, n (%) 15 (163) 13 (155)
Median (range) 40 (0–17) 35 (0–15)
WBC (9109/l)
<50, n (%) 61 (663) 48 (571)
50–<100, n (%) 13 (141) 21 (250)
≥100, n (%) 18 (196) 15 (179)
Median (range) 363 (18–650) 375 (36–550)
NCI risk group
Standard risk, n (%) 50 (543) 41 (488)
High risk, n (%) 42 (457) 43 (512)
EORTC risk group
Standard risk (RF < 12), n (%) 1 (11) 0 (00)
Medium risk (RF 12–<17),
n (%)
79 (859) 74 (881)
High risk (RF ≥ 17), n (%) 12 (130) 10 (119)
EFS status
Alive, in CR1, without SN,
n (%)
59 (641) 52 (619)
Relapse, n (%) 28 (304) 24 (286)
Any CNS, n (%) 8 (87) 10 (120)
CNS isolated, n (%) 6 (65) 4 (48)
CNS combined, n (%) 2 (22) 6 (72)
BM isolated, n (%) 15 (163) 10 (119)
BM combined (non-CNS),
n (%)
2 (22) 2 (24)
Other only, n (%) 3 (33) 2 (24)
SN in CR1, n (%) 3 (33) 8 (95)
SN still alive, n (%) 3 (33) 7 (83)
SN followed by death, n (%) 0 (00) 1 (12)
Death in CR1, without SN,
n (%)
2 (22) 0 (00)
DFS
25-year rate, % (SE) 674 (49) 702 (50)
HR (95% CI) 108 (063–183)
SN in CR1
25-year incidence, % (SE) 79 (46) 110 (42)
HR (95% CI) 035 (009–133)
EFS
25-year rate, % (SE) 595 (63) 605 (59)
HR (95% CI) 094 (057–152)
Survival/SN status
Alive without SN, n (%) 68 (739) 58 (690)
SN, n (%) 4 (44) 9 (107)
Death without SN, n (%) 20 (217) 17 (203)
Table I. (Continued)
No CRT CRT
92 (100%) 84 (100%)
SN
25-year incidence, % (SE) 73 (43) 130 (46)
HR (95% CI) 043 (013–141)
Survival status
Death due to any cause, n (%) 20 (217) 18 (214)
OS
25-year rate, % (SE) 781 (43) 785 (45)
HR (95% CI) 100 (053–188)
BM, bone marrow; CI, confidence interval; CNS, central nervous sys-
tem; CR1, first complete remission; CRT, cranial radiotherapy; DFS,
disease-free survival (event: relapse, death in CR1); EFS, event-free
survival (event: relapse, SN in CR1, death in CR1 and without SN);
HR, hazard ratio; OS, overall survival; SN, second neoplasm; WBC,
white blood cells.
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Patients randomized in the No CRT arm had similar 25-
year incidence of any (87% vs. 119%) and of isolated (65%
vs. 48%) CNS relapse compared to the CRT arm. A recent
retrospective meta-analysis evaluated the influence of CRT
on the outcome of childhood ALL patients, based on aggre-
gate data from 16,623 ALL children aged 1–18 years and
treated in ten collaborative trials. In two trials [DCOG ALL-
9 (Veerman et al., 2009) and Total Therapy XV (Pui et al.,
2009)], CRT was not part of first-line treatment, while in the
eight other studies, CRT was restricted to 2–33% of the
patients, considered to be at high risk of CNS relapses. In
non-CNS3 patients, there was no benefit for CRT in terms of
incidence of any CNS relapse, isolated CNS relapse and sur-
vival at five years (Vora et al., 2016). In patients with CNS-3
status, the rates of any and isolated CNS relapse were higher
without CRT (167% vs. 68% and 167% vs. 43% respec-
tively), with similar five-year mortality rates.
In the initial publication of EORTC studies 58831 and
58832 (Vilmer et al., 2000), including 707 standard- and
medium/high-risk patients, the 10-year incidence of any CNS
Fig 3. (A) Kaplan–Meier curve of disease-free
survival [event: relapse, death in first complete
remission (CR1)] and cumulative incidence of
any central nervous system (CNS) relapse. (B)
Kaplan–Meier curve of event-free survival
[event: relapse without second neoplasm (SN),
SN in CR1, death in CR1 and without SN]
and cumulative incidence of SN in CR1. (C)
Kaplan–Meier curve of overall survival by
treatment arm [No cranial radiotherapy (CRT)
or CRT].
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relapse was approximately 10%, and was comparable to that
of the similar ALL-BFM 83 study (87%) (M€oricke et al.,
2010). In the EORTC study, only 12% received CRT in CR1
whereas in the BFM study, 70% of the patient population
had to receive CRT (at age-dependent dose), including the
CNS-3 patients (29%).
The eight-year incidence of any and isolated CNS relapse
progressively decreased in subsequent EORTC studies,
despite the omission of CRT for all patients in CR1: 76%
and 36% respectively in study 58881 (1989–1998) (Sirvent
et al., 2011), and 37% and 17% in study 58951 (1998–
2008) (Domenech et al., 2014). DCOG and St. Jude also
omitted CRT for all patients in their respective ALL-9 (Veer-
man et al., 2009) and Total Therapy XV (Pui et al., 2009)
studies, and reported isolated CNS relapse incidences of
26% and 27% respectively. In their subsequent ALL-10
study, DCOG administered CRT at 12 Gy in high-risk
patients older than three years who were not receiving stem
cell transplantation (06% of the patients) and reported a
five-year isolated CNS relapse incidence of 14% (Pieters
et al., 2016). In the current Total Therapy XVI, St. Jude
omits CRT in all patients but intensifies the systemic CNS
prophylaxis (e.g. up to 27 intrathecal injections) for stan-
dard/high-risk patients at high risk of CNS relapse [CNS
positive, WBC ≥ 100 9 109/l, T-cell ALL, t(1;19)/E2A-PBX1,
presence of Philadelphia chromosome, MLL rearrangement,
hypodiploidy <44]. In the current EORTC 58081 study, CRT
is not part of the first-line treatment strategy. MTX is
infused at the dose of 5 g/m2, and leucovorin is given at the
dose of 12 mg/m2 at 6-h intervals, from 42 h until 72 h after
the start of MTX infusion, or until MTX serum level is
<2 9 107 mol/l. The use of PEGylated asparaginase and the
monitoring of its activity are recommended, since L-asparagi-
nase plays a role in preventing CNS relapses (Sirvent et al.,
2011). Patients with CNS-3 status receive dexamethasone
during induction or receive a higher cumulative dose of dex-
amethasone during late intensification, depending on their
initial risk group. The number of intrathecal chemotherapy
injections ranges from 11 in CNS-negative very low-risk
patients to 22 in CNS-3 very high-risk patients.
The 20-year median follow-up enabled us to assess the
incidence of SN, since solid SN are known to occur late in
follow-up. Interestingly, we found female predominance in
patients who developed SN, while the entire patient popula-
tion showed male predominance. St. Jude reported no sex
impact on SN incidence at 20 years from ALL diagnosis, but
did observe an increased cumulative incidence of SN at
30 years in females as compared to males (Hijiya et al.,
2007). In the general population, neoplasms are less common
in females, except for some subtypes, such as thyroid cancers
(F/M ratio: 3) or meningiomas (F/M ratio: 2). In our study,
basically all meningiomas occurred after 20 years from ALL
diagnosis, and the F/M ratio was 15. In addition, our results
are in line with previous observations documenting a positive
association between CRT and SN incidence (Casagranda
et al., 2016), particularly for meningiomas (Carret et al.,
2006; Renard et al., 2011; Schmiegelow et al., 2013). Also, St.
Jude reported an increasing 20-year cumulative incidence of
brain tumours with increasing irradiation dose: 1% at 10–
21 Gy, 17% at >21–30 Gy and 32% at >30 Gy (Walter
et al., 1998). In our cohort, no patient below the age of two
developed SN of the CNS, possibly due to the lower CRT
doses administered in younger patients (16 Gy < 1 year,
20 Gy 1– <2 years and 24 Gy ≥ 2 years).
In our study, increased rate of leukoencephalopathy
(192%) was associated with the use of CRT and of higher
doses of MTX, corroborating previous findings. A recent
review reported chronic leucoencephalopathy in 18–61% of
childhood ALL survivors systematically evaluated by imaging
(Partap et al., 2019). Among patients treated in the Total
Table III. Distribution of the late adverse effects according to the treatment (EORTC study 58 831 and No CRT vs CRT in EORTC study
58 832).
Type of LAE
(CTCAE 4.0, grades 1–4)
EORTC study 58 831*
EORTC study 58 832†
No CRT (N = 272)
N observed LAE/N
available data (%)
No CRT (N = 92)
N observed LAE/N
available data (%)
CRT (N = 84)
N observed LAE/N
available data (%)
Leukoencephalopathy 1/61 (1.6) 2/23 (8.7) 5/26 (19.2)
Cognitive disturbance 4/64 (6.3) 3/16 (18.8) 8/19 (42.1)
Seizures 11/101 (10.9) 1/27 (3.7) 4/28 (14.3)
Stroke 1/90 (1.1) 0/26 (0.0) 2/26 (7.7)
GH deficiency 8/88 (9.1) 5/27 (18.5) 17/32 (53.1)
Hypothyroidism 3/61 (4.9) 0/18 (0.0) 5/18 (27.8)
Precocious puberty 2/60 (3.3) 0/18 (0.0) 5/17 (29.4)
Delayed puberty 5/59 (8.5) 2/19 (10.5) 2/16 (12.5)
CRT, cranial radiotherapy; GH, growth hormone; LAE, late adverse effects.
*Methotrexate injections at 0.5 g/m2 during interval therapy.
†Intermediate-dose methotrexate injections at 2.5 g/m2 during interval therapy.
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Therapy XV protocol without CRT and with fve administra-
tions of high-dose MTX and 13 to 25 triple IT, all symp-
tomatic patients and 206% of asymptomatic patients had
leukoencephalopathy on systematic MRI evaluation, which
persisted in 58% of symptomatic and 74% of asymptomatic
patients at the end of therapy (Bhojwani et al., 2014). Acute
leckoencephalopathy was associated with higher risk for
long-term neurocognitive impairment. We observed a higher
rate of cognitive disturbance (421%) in the CRT arm. Both
CRT and, to a lesser extent, chemotherapy are recognized as
major risk factors. We observed a fourfold increase in the
rate of seizures in the CRT arm (143%). Very few data
report on the incidence and risk factors of seizures after
childhood ALL. Goldsby et al reported an incidence of 20-
year seizures of 7% in childhood ALL survivors and did not
identify CRT as a risk factor (Goldsby et al., 2010). In our
study, the rate of seizures observed in patients treated with-
out CRT and with MTX at 05 g/m2 in study 58831 seemed
unexpectedly high in comparison with that of patients trea-
ted without CRT and with MTX at 5 g/m2 in study 58832.
Unfortunately, we did not find the aetiology in 8 of the 11
standard-risk patients who developed seizures, making it dif-
ficult to draw conclusions regarding the impact of MTX dose
on the development of seizures.
A higher proportion of patients randomized in the CRT
arm developed endocrine disorders, including GH deficiency
(531%). This is consistent with previous observations
reporting a negative impact of CRT on adult height
through GH deficiency, particularly after doses ≥18 Gy
(Stubberfield et al., 1995; Melin et al., 1998). The effect of
chemotherapy on growth velocity is rather linked to decline
in insulin-like growth factor and insulin-like growth factor-
binding protein 3 levels during initial and continuation
therapy but is usually followed by catch-up growth (Sch-
miegelow et al., 1999). Hypothyroidism was observed in
278% in the CRT arm, and in 0% in the No CRT arm.
This latter observation is in line with previous reports indi-
cating normal thyroid function in patients treated with
chemotherapy alone (Howard & Pui, 2002). In contrast, the
literature is conflicting regarding the impact of CRT. The
Childhood Cancer Survivor Study observed patient-reported
hypothyroidism in 4% and 68% of ALL survivors treated
without and with CRT respectively (Chow et al., 2013).
Consistently, Steffens et al. found no difference in the rate
of hypothyroidism based on TSH/T4 levels in patients trea-
ted without (6%) and with CRT (14%), but identified TBI
as a risk factor (Steffens et al., 2008). Our data also support
a strong negative impact of TBI on thyroid function.
Finally, we observed an association between CRT and pre-
cocious puberty, and between TBI and delayed puberty.
This is in line with previous reports suggesting that delayed
puberty seems related to primary gonadic dysfunction
rather than to hypopituitarism.
In conclusion, our observations, based on very-long-term
follow-up, add to the body of evidence that, with proper
systemic and intrathecal CNS prophylaxis, CRT could totally
be omitted in CR1 without jeopardizing OS while decreasing
the long-term adverse events in ALL children. Long-term
prospective studies will be needed to evaluate the impact of
intensified systemic CNS prophylaxis on the neurocognitive
outcome (Jacola et al., 2016) and the health-related quality
of life (Vetsch et al., 2018) of ALL survivors and optimal
schedules need to be established.
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